Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Enspryng is a prescription monoclonal antibody containing satralizumab-mwge. It is an interleukin-6 receptor antagonist indicated for neuromyelitis optica spectrum disorder in adults who are positive for anti-aquaporin-4 antibodies. The medicine is given by subcutaneous injection using a prefilled syringe or autoinjector.
read more about enspryng ...Satralizumab binds soluble and membrane-bound interleukin-6 receptors and inhibits IL-6-mediated signaling. The precise way this action produces therapeutic effects in neuromyelitis optica spectrum disorder is not known. IL-6 signaling participates in inflammatory immune activity involved in the disease.
Enspryng is approved for adults with neuromyelitis optica spectrum disorder who test positive for anti-aquaporin-4 antibodies. Current U.S. labeling does not establish pediatric use. Hepatitis B, tuberculosis, liver enzymes, and bilirubin are assessed before the first dose, and active infections are addressed before an injection.
The recommended dose is 120 mg by subcutaneous injection at weeks 0, 2, and 4. Maintenance treatment then continues with 120 mg every four weeks. Liver enzymes are monitored regularly during treatment, and neutrophil counts are checked after treatment begins and at clinically determined intervals.
Serious concerns include infections, elevated liver enzymes, reduced neutrophil counts, and hypersensitivity reactions. Active hepatitis B and active or untreated latent tuberculosis are contraindications. Live or live-attenuated vaccines are avoided during treatment, and immunizations are completed according to current guidance before therapy begins.
Enspryng treats AQP4-antibody-positive neuromyelitis optica spectrum disorder in adults.
The first three 120 mg doses are given at weeks 0, 2, and 4.
After loading, the maintenance dose is 120 mg every four weeks.
Current labeling calls for hepatitis B, tuberculosis, liver enzyme, and bilirubin assessment before treatment.
ENSPRYNG (Satralizumab-mwge) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=64c156a4-9bad-4d45-a294-0733c141f47b. Date Accessed September 29, 2026.
Orphan Drug Designations and Approvals: Satralizumab-mwge. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=436114. Date Accessed September 29, 2026.
Safety and Efficacy of Satralizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: A Randomised, Double-Blind, Multicentre, Placebo-Controlled Phase 3 Trial. https://pubmed.ncbi.nlm.nih.gov/32333898/. Date Accessed September 29, 2026.
Satralizumab-mwge Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a620065.html. Date Accessed September 29, 2026.
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. https://pubmed.ncbi.nlm.nih.gov/31774956/. Date Accessed September 29, 2026.